The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

The government asserted that Biohaven’s fraud stopped in October 2022, when Pfizer acquired the company and terminated the Nurtec speaker programmes. "We are pleased to put this legacy matter ...

Pfizer, on behalf of its subsidiary Biohaven Pharmaceutical Holding Company, agreed to pay $59,746,277 to resolve allegations that prior to Pfizer's acquisition, Biohaven paid kickbacks to physicians ...

Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven. "Patients deserve to know that their doctor is prescribing medications based on their doctor’s medical ...

World-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A ...

The kickbacks were meant to encourage doctors to prescribe the migraine drug Nurtec ODT, which is a violation of the False Claims Act, the U.S. Department of Justice said. In October 2022 ...

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec. Healthcare lease accounting insights: How two organizations ...

Nurtec ODT (rimegepant) is a brand-name drug prescribed for treating and preventing migraine in adults. Nurtec ODT comes as a tablet that dissolves in your mouth. The dosage can vary depending on ...